Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Aronia melanocarpa (black chokeberry) has been studied for its potential benefits in diabetic retinopathy due to its high content of polyphenols, particularly anthocyanins, which possess strong antioxidant and anti-inflammatory properties. Laboratory and small clinical studies suggest that oxidative stress and inflammation play key roles in the pathogenesis of diabetic retinopathy, and compounds that reduce oxidative damage may help mitigate disease progression. A few animal studies have demonstrated that aronia extracts can reduce retinal oxidative stress, inhibit vascular leakage, and improve retinal structure in diabetic models. Additionally, limited human studies, such as small-scale clinical trials or pilot studies, have shown improvements in oxidative stress markers and microcirculation in diabetic patients after supplementation with aronia berry extracts. However, these studies are generally small, short-term, or preliminary, and robust, large-scale randomized controlled trials in patients with established diabetic retinopathy are lacking. Therefore, while there is a plausible scientific rationale and some early evidence supporting the use of Aronia melanocarpa for diabetic retinopathy, the overall quality and quantity of evidence is currently limited, warranting a moderate-low evidence rating.

More about Aronia melanocarpa
More about Diabetic Retinopathy

Other ingredients used for Diabetic Retinopathy

Other health conditions supported by Aronia melanocarpa

Products containing Aronia melanocarpa